Compare Patterson-UTI Energy Inc. Common Stock (PTEN) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Patterson-UTI Energy Inc. Common Stock vs Repligen Corporation Common Stock — how do they compare? Patterson-UTI Energy Inc. Common Stock trades at $11.6 (market cap $4.39B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 2.5× Patterson-UTI Energy Inc. Common Stock's market cap, and Patterson-UTI Energy Inc. Common Stock pays a 3.48% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Patterson-UTI Energy Inc. Common Stock for 3 Days and Repligen Corporation Common Stock for 0 Days on average.
| PTEN | RGEN | |
|---|---|---|
Market Cap | $4.39B | $11.14B |
Volume | 4,811,496 | 1,259,263 |
Sector | Energy | Health |
52-Week High | $13.15 | $194.57 |
52-Week Low | $5.41 | $102.87 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $5.47B | $11.02B |
Dividend Yield | 3.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Patterson-UTI Energy (PTEN) trades at $11.52, up 1.68% today, with a neutral technical signal. The stock shows strong cash flow from operations at $961.22M for 2025, but net income remains negative at -$93.64M. Recent earnings beats and an upcoming Q3 2026 report on October 29, 2026, highlight operational momentum, supported by an average of 103 drilling rigs in September 2026. Analyst consensus is bullish with a $13.38 price target, indicating a 16% upside.
The outlook is cautiously optimistic due to earnings consistency and positive analyst sentiment, but risks include persistent net losses, exposure to oil price volatility, and competitive pressures. Upside potential hinges on sustained rig demand and profitability improvements, while downside risks stem from macroeconomic headwinds affecting energy sectors.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Patterson-UTI Energy Inc. Common Stock
Patterson-UTI Energy provides drilling, completion, and other oilfield services for oil and gas producers in the United States.
Read more on PTEN →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
